Table 2 Adverse events by preferred terms in the Latin American study population
Patients with AEs, n (%) | Early combination n = 267 n (%) | Initial monotherapy n = 270 n (%) |
|---|---|---|
Patients with at least one AE | 240 (89.8) | 230 (85.2) |
Diarrhea | 47 (17.6) | 36 (13.3) |
Back pain | 41 (15.4) | 32 (11.9) |
Influenza | 41 (15.4) | 24 (8.9) |
Arthralgia | 40 (15.0) | 43 (15.9) |
Urinary tract infection | 34 (12.7) | 29 (10.7) |
Hypertension | 34 (12.7) | 39 (14.4) |
Nasopharyngitis | 33 (12.4) | 38 (14.1) |
Headache | 31 (11.6) | 28 (10.4) |
Pain in extremity | 31 (11.6) | 42 (15.6) |
Anxiety | 18 (6.7) | 31 (11.5) |
Dyslipidemia | 23 (8.6) | 27 (10.0) |
Pharyngitis | 21 (7.9) | 22 (8.1) |
Hypertriglyceridemia | 20 (7.5) | 10 (3.7) |
Bronchitis | 16 (6.0) | 13 (4.8) |
Gastroenteritis | 14 (5.2) | 16 (5.9) |
Abdominal pain | 13 (4.9) | 14 (5.2) |
Hepatic steatosis | 13 (4.9) | 9 (3.3) |